

Stryker Dominates the U.S. Minimally Invasive Bunion Device Market Despite COVID-19

VANCOUVER, BRITISH COLUMBIA, CANADA, October 21, 2021

[/Einpresswire.com/](https://www.einpresswire.com/) -- iData Research ("iData"), a global consulting and market research firm, has unveiled updated insights on the [U.S. minimally invasive bunion device market](#). iData's analysis addresses brand-level metrics including average selling prices (ASPs), revenue by brand, market share by revenue, market share by unit, and total units sold. Based on the data, revenue and units sold minimally decreased, in general, in Q2' 20 as COVID-19 hit. Despite this, both revenue and units sold have begun climbing back up to pre-COVID levels but have yet to exceed historical numbers.



iData's analysts utilized primary data from 1000s of reporting hospitals and ambulatory surgery centers (ASCs) to gather accurate data and sales information for the updated reports. After combining this with rigorous primary research, ongoing for over a decade, a cross-verified and highly accurate depiction of the market was developed.

“

Most orthopedic procedures, throughout 2020, were not deemed essential. Because of this, a lot of markets experienced declines, including the U.S. minimally invasive bunion device market.”

Dr. Kamran Zamanian, Senior Partner and CEO

Throughout the analysis on the U.S. minimally invasive bunion device market, 13 companies and over 50 brands were analyzed within three market segments including screw, k-wire, and burr. The insights obtained from the updated market analysis generated expected results. Overall, the revenue and units sold decreased due to COVID-19. The global pandemic wreaked havoc on many markets and further influenced the decline within the U.S. minimally invasive bunion device market. Despite this, the

aggregate data indicates that, overall, the companies were able to recover by Q3' 20 and

continue growing into Q2 '21 and beyond.

Out of all 13 companies, Stryker was able to remain dominant in terms of overall revenue generated. Arthrex and Acumed, following by a substantial margin, were able to generate the second and third largest revenues, independent of Stryker. Despite Acumed generating a significant amount of revenue, the company suffered in both Q1 and Q2 '20. Since then, Acumed has been able to recover but has been struggling to maintain consistent growth, leaving room for others to overtake them in terms of revenue share.

For a full overview of the U.S. minimally invasive bunion device market, follow the link below and view the MedSKU solution in detail:

<https://idataresearch.com/mis-bunion-devices-top-brands-per-segment-in-the-u-s/>

For Further Information

More insights like this can be found in the latest reports by iData. Please email us at info@idataresearch.net or register online for a brochure and synopsis.

About MedSKU

MedSKU (™) is an accurate brand-level custom solution from iData that provides a level of detail for a go-to strategy of medical device companies of any size. The analysis of infusion pumps is one of many studies that provide up-to-date data and trends on the ASPs, units sold, unit share, revenue, and revenue shares of the top-performing products in the U.S.

About iData

iData Research is an international consulting and market research firm dedicated to empowering confident strategic decisions within the medical device, dental, and pharmaceutical industries.

<https://idataresearch.com/medsku/>

Emma Matrick
iData Research
+1 604-266-6933
[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/554355701>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.